RBC Capital starts Fulcrum Therapeutics at Outperform, sees two pipeline shots

As previously reported, RBC Capital initiated coverage of Fulcrum Therapeutics with an Outperform rating and $14 price target. The company offers two distinct pipeline shots on goal in genetically defined rare diseases, the analyst tells investors in a research note, calling the stock a rejuvenation story. The first, an oral small molecule p38alpha/beta dual inhibitor losmapimod has potential as the first therapy for facioscapulohumeral muscular dystrophy with potential for worldwide sales of $900M through 2030, while the second – pociredir – is an early-stage asset that brings a validated mechanism to sickle cell disease, RBC added.